Overview
The goal of this double-blinded, randomized cross-over clinical trial is to assess the isolated (i.e. outside the context of exercise) effects of Lac-Phe on appetite and glucose concentrations in healthy volunteers with obesity (BMI 28-35).
The main questions it aims to answer are:
- Does Lac-Phe reduce appetite in humans?
- Does Lac-Phe have glucose-lowering properties in humans?
During the study, participants will:
- receive an intravenous infusion of Lac-Phe on one study day and a NaCl infusion on another study day.
- drink a standard mixed meal
- eat an ad libitum meal test
- answer appetite questionnaires
- indirect calorimetry
- blood samples for hormone and substate analyses
Eligibility
Inclusion Criteria:
- A body mass index (BMI) between 28-35 kg/m2
- Older than 18 years of age
- Hgb within a normal range (females: 7.3-9.5 mmol/L, males: 8.3-10.5 mmol/L)
- Females can be included if they are either postmenopausal or actively use hormonal contraception (e.g., oral contraceptive pill or hormone-releasing intrauterine device).
Exclusion Criteria:
- Medications affecting glucose metabolism (e.g., Saxenda).
- Anemia
- Diabetes
- Ongoing cancer or other acute/chronic serious diseases (PI will determine)
- Inability to understand Danish or English
- Deemed unsuitable to participate by the PI and co-investigators.